Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials

Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials

<strong>Background</strong> The net absolute effects of sodium-glucose co-transporter-2 (SGLT-2) inhibitors across different patient groups have not been quantified. <br> <strong>Methods</strong> We performed a meta-analysis of published large (>500 participants/arm)...

Full description

Bibliographic Details
Main Authors:	Staplin, N, Roddick, AJ, Emberson, J, Reith, C, Riding, A, Wonnacott, A, Kuverji, A, Bhandari, S, Baigent, C, Haynes, R, Herrington, WG
Format:	Journal article
Language:	English
Published:	Elsevier 2021

Similar Items

Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials
by: Natalie Staplin, PhD, et al.
Published: (2021-11-01)

Impact of diabetes on the effects of sodium glucose co-transporter-2 (SGLT2) inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
by: Herrington, W, et al.
Published: (2022)

UK Kidney Association clinical practice guideline: sodium-glucose co-transporter-2 (sglt-2) inhibition in adults with kidney disease 2023 update
by: Roddick, AJ, et al.
Published: (2023)

UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease 2023 UPDATE
by: Alistair J. Roddick, et al.
Published: (2023-10-01)

Cardiac, renal, and metabolic effects of sodium–glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium–glucose co-transporter 2 inhibitors
by: Herrington, WG, et al.
Published: (2021)

Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)
by: Herrington, WG, et al.
Published: (2023)

Use of causal diagrams to inform the analysis and interpretation of observational studies: An example from the Study of Heart and Renal Protection (SHARP)
by: Staplin, N, et al.
Published: (2016)

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
by: Herrington, W, et al.
Published: (2018)

Evidence for the prevention and treatment of stroke in dialysis patients
by: Herrington, W, et al.
Published: (2014)

Conventional and genetic evidence on the association between adiposity and CKD
by: Zhu, P, et al.
Published: (2020)

Apolipoprotein B, triglyceride-rich lipoproteins, and risk of cardiovascular events in persons with CKD
by: Lamprea-Montealegre, J, et al.
Published: (2019)

Conventional and genetic evidence on the association between adiposity and chronic kidney disease
by: Zhu, P, et al.
Published: (2020)

Evaluating the contribution of the cause of kidney disease to prognosis in ckd: Results from the Study of Heart and Renal Protection (SHARP)
by: Haynes, R, et al.
Published: (2014)

Evaluating the contribution of the cause of kidney disease to prognosis in CKD: results from the Study of Heart and Renal Protection (SHARP).
by: Haynes, R, et al.
Published: (2014)

Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
by: Storey, B, et al.
Published: (2017)

Cross-sectional associations between central and general adiposity with albuminuria: observations from 400,000 people in UK Biobank
by: Zhu, P, et al.
Published: (2020)

Cost-effectiveness of lowering LDL cholesterol with statins and ezetimibe in chronic kidney disease
by: Mihaylova, B, et al.
Published: (2019)

Effects of sodium-glucose cotransporter 2 inhibitors on cause-specific cardiovascular death in patients with CKD
by: Fletcher, RA, et al.
Published: (2024)

The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection.
by: Herrington, W, et al.
Published: (2014)

Impact of CKD on household income
by: Morton, R, et al.
Published: (2017)

Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease
by: Herrington, W, et al.
Published: (2016)

Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (the 3C Study) – results of a randomized controlled clinical trial
by: Haynes, R, et al.
Published: (2018)

Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy
by: Storey, B, et al.
Published: (2018)

Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP)
by: Staplin, N, et al.
Published: (2015)

Fibroblast growth factor-23 and risk of cardiovascular diseases: a Mendelian randomization study
by: Donovan, K, et al.
Published: (2022)

Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: Results from the study of heart and renal protection
by: Reith, C, et al.
Published: (2017)

Determining the relationship between blood pressure, kidney function, and chronic kidney disease: insights from genetic epidemiology
by: Staplin, N, et al.
Published: (2022)

A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease
by: Schlackow, I, et al.
Published: (2017)

Angiotensin receptor blockers and β-blockers in Marfan syndrome: an individual-patient-data meta-analysis of randomised trials
by: Pitcher, A, et al.
Published: (2022)

Kidney disease trials for the 21st century: innovations in design and conduct
by: Herrington, W, et al.
Published: (2019)

Sodium, Glucose and Dysregulated Glucagon Secretion: The Potential of Sodium Glucose Transporters
by: Sarah L. Armour, et al.
Published: (2022-02-01)

Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection
by: C. Reith, et al.
Published: (2017-05-01)

Smoking and adverse outcomes in patients With CKD: the Study of Heart and Renal Protection (SHARP)
by: Emberson, J, et al.
Published: (2016)

Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials
by: Cholesterol Treatment Trialists' Collaboration, et al.
Published: (2016)

Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
by: Mayne, K, et al.
Published: (2024)

Use of gel-based separator tubes to stabilise phosphate in mailed blood samples.
by: Herrington, W, et al.
Published: (2015)

Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection.
by: Mafham, M, et al.
Published: (2017)

Benefits of lowering cholesterol in chronic kidney disease Reply
by: Baigent, C, et al.
Published: (2011)

Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial
by: Mayne, KM, et al.
Published: (2024)

The authors reply
by: Chapman, D, et al.
Published: (2023)